Immunogenicity and Safety of COVID-19 Vaccines in Patients with Lung Cancer: Results of a Systematic Review and Meta-Analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.COVID-19 vaccination in lung cancer patients shows comparable safety to healthy individuals but results in significantly lower antibody titers. Continued protective measures are essential for this vulnerable population.
Area Of Science
- Immunology
- Oncology
- Vaccinology
Background
- The COVID-19 pandemic presents a significant global health challenge.
- Vaccination is crucial for reducing transmission and protecting individuals.
- Assessing the immunogenicity and safety of COVID-19 vaccines in high-risk groups like lung cancer patients is critical.
Purpose Of The Study
- To evaluate the safety and immunogenicity of COVID-19 vaccinations in patients with lung cancer.
- To compare antibody responses and adverse events in lung cancer patients versus healthy controls.
Main Methods
- A systematic literature search was performed in PubMed, EMBASE, and Web of Science (Jan 2021-Nov 2022).
- Included studies involved at least 30 lung cancer patients on active therapy and healthy controls, assessing anti-SARS-CoV-2-spike IgG titers and adverse events post-vaccination.
- Eight studies comprising 1,220 lung cancer patients and 599 controls met the inclusion criteria.
Main Results
- Lung cancer patients exhibited significantly lower IgG titers against the SARS-CoV-2-spike protein compared to healthy controls (p = 0.002).
- The safety profiles were comparable between lung cancer patients and healthy individuals, with similar rates of local and systemic adverse reactions after both vaccine doses.
Conclusions
- Lung cancer patients demonstrate a markedly reduced antibody titer post-COVID-19 vaccination compared to healthy individuals.
- Despite vaccination, lung cancer patients remain at risk for COVID-19 fatalities.
- Enhanced protective measures are imperative for vaccinated lung cancer patients to mitigate COVID-19 risks.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...